Form 4: Thermo Fisher Scientific CEO Marc Casper Sells Shares Under 10b5-1 Trading Plan

Thermo Fisher Scientific's CEO, Marc Casper, executed multiple sales of company stock on November 6th and 7th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Marc Casper, the Chairman and CEO of Thermo Fisher Scientific, sold shares of the company's common stock on November 6th and 7th, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 7, 2024.
• On November 6th, Casper sold a total of 9,900 shares at prices ranging from $551.49 to $567.68.
• On November 7th, he sold a total of 10,099 shares at prices ranging from $555.31 to $563.15.
• Following these transactions, Casper directly owns 121,191.54 shares and indirectly owns shares through Floral Park Associates, Inc. (23,608), Alison Casper 2020 Irrevocable Trust (11,300), and MNC 2020 Irrevocable Trust (5,000).

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock sales under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although sales under a 10b5-1 plan are generally viewed as less concerning since they are pre-planned.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates